Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Euronext Paris  >  Adocia    ADOC   FR0011184241

ADOCIA

(ADOC)
  Report
 SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Euronext Paris
02/17/2020 02/18/2020 02/19/2020 02/20/2020 02/21/2020 Date
12.48(c) 11.96(c) 12.1(c) 12.02(c) 11.14(c) Last
13 352 44 441 14 094 13 622 60 806 Volume
-1.42% -4.17% +1.17% -0.66% -7.32% Change
More quotes
Financials (EUR)
Sales 2019 15,9 M
EBIT 2019 -21,5 M
Net income 2019 -22,0 M
Finance 2019 9,40 M
Yield 2019 -
Sales 2020 38,0 M
EBIT 2020 -5,38 M
Net income 2020 -15,6 M
Debt 2020 8,80 M
Yield 2020 -
P/E ratio 2019 -3,51x
P/E ratio 2020 -4,95x
EV / Sales2019 4,27x
EV / Sales2020 2,27x
Capitalization 77,4 M
More Financials
Company
Adocia is a biotechnology company that specializes in the development of innovative formulations of already-approved therapeutic proteins s for the treatment of diabetes. At the end of 2018, the group had a portfolio of 6 products in clinical development (BioChaperone Lispro U100 and U200,... 
More about the company
Latest news on ADOCIA
01/31ADOCIA : Monthly statement on outstanding equity shares and voting rights
CO
01/10ADOCIA : Half Year Report on Adocia's Liquidity Agreement With Kepler Capital Ma..
BU
2019ADOCIA : Monthly statement on outstanding equity shares and voting rights
CO
2019ADOCIA : Announces Its Financial Calendar for 2020
BU
2019ADOCIA : Announces the Subscription of the Second Tranche of the Financing Line ..
BU
2019ADOCIA : Provisional calendar
CO
2019ADOCIA : 3rd quarter earnings
CO
2019ADOCIA : 3rd quarter results
CO
2019ADOCIA : Monthly statement on outstanding equity shares and voting rights
CO
2019ELI LILLY AND COMPANY : - Arbitration panel rules in favor of Lilly in complaint..
AQ
2019ADOCIA : Monthly statement on outstanding equity shares and voting rights
CO
2019ADOCIA : Half-year results
CO
2019ADOCIA : Monthly statement on outstanding equity shares and voting rights
CO
2019ADOCIA : Half-year report
CO
2019ADOCIA : 1st quarter results
CO
More news
News in other languages on ADOCIA
01/27ADOCIA : parmi les plus fortes baisses du SRD à la clôture du lundi 27 janvier 2..
01/27ADOCIA : plus forte baisse du SRD à la mi-séance du lundi 27 janvier 2020
01/23ADOCIA : plus forte hausse du SRD à la clôture du jeudi 23 janvier 2020
01/23ADOCIA : plus forte hausse du SRD à la mi-séance du jeudi 23 janvier 2020
01/10ADOCIA : Bilan semestriel du contrat de liquidité Adocia conclu avec la société ..
More news
Analyst Recommendations on ADOCIA
More recommendations
Sector news : Bio Therapeutic Drugs
02/20Anglo American Discloses All Mine Deaths in Industry Shift--Update
DJ
02/20Anglo American Discloses All Mine Deaths in Industry Shift -- Update
DJ
02/20Anglo American Discloses All Mine Deaths in Industry Shift
DJ
02/20GlaxoSmithKline Invests $50 Million in Biotech Startup's Cell-Therapy Program
DJ
02/19Five Prime Therapeutics In License Agreement with Seattle Genetics
DJ
More sector news : Bio Therapeutic Drugs
Chart ADOCIA
Duration : Period :
Adocia Technical Analysis Chart | ADOC | FR0011184241 | MarketScreener
Technical analysis trends ADOCIA
Short TermMid-TermLong Term
TrendsNeutralBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 1
Average target price 14,00  €
Last Close Price 11,14  €
Spread / Highest target 25,7%
Spread / Average Target 25,7%
Spread / Lowest Target 25,7%
EPS Revisions
Managers
NameTitle
Gérard Soula Chairman & Chief Executive Officer
Valérie Danaguezian Chief Financial Officer & Administrative Director
Olivier Soula Director, Director-R&D, Deputy CEO
Martin Gaudier Director-Scientific
Olivier Martinez Director
Sector and Competitors
1st jan.Capitalization (M$)
ADOCIA12.53%84
GILEAD SCIENCES3.11%88 181
VERTEX PHARMACEUTICALS12.49%63 855
REGENERON PHARMACEUTICALS6.30%43 886
WUXI APPTEC CO., LTD.22.35%26 379
GENMAB A/S14.61%16 125